Home / Products / Cancer / Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Available treatments for Acute Lymphoblastic Leukemia
You can order a treatment for Acute Lymphoblastic Leukemia via TheSocialMedwork if it has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
View Product


(inotuzumab ozogamicin)

by: Pfizer
for: Acute Lymphoblastic Leukemia
from: 14272.00
• EMA approved (EU)
• FDA approved (USA)

View Product



by: Amgen
for: Blood Cancer
from: 3010.50
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

Enquire now

We may still be able to get it for you, provided that:

• it hasn't been approved and/or isn't available in your country
• you and your treating doctor have evaluated that the medicine is suitable for you, and your doctor writes a prescription for it.

About acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia or acute lymphoid leukemia, is a cancer of the lymphocytes, a type of white blood cells, the cells that constitute the immune system [1]. It results from an overproduction of lymphoblasts (immature lymphocytes) in the bone marrow. Leukemia cells usually invade the blood fairly quickly and they can then spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). The term acute refers to the fact that this type of leukemia can progress quickly, the bone marrow cells cannot mature properly and immature lymphocytes continue to reproduce and accumulate [2].

There are two main types of lymphocytes called B-cells and T-cells [3]. The majority of ALL cases are of B-cell origin but it can also arise from T-cell precursors. ALL is the most common cancer in children. Global incidence is about 3 per 100,000 population, with about 3 out of 4 cases occurring in children aged under 6 years. ALL represents 12% of all leukemia (but 80% in children). Peak age of incidence occurs between the ages of 2-4 years, however, a smaller peak occurs in people aged over 50 years. [4]

The above products may be suitable for treating patients with ALL. We recommend that you discuss the suitability of possible treatment options with your doctor. For further information please contact our support team at support@thesocialmedwork.com.

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Share our website

Follow us

DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.